Oragenics, Inc.

A textual analysis of the financial results for Oragenics, Inc. compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business description of the company, including contact information, senior officers and Wright Quality Rating analyses is also provided. SYNOPSIS Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio tables (Accounting, Asset Utilization, Employee Efficiency, Fixed Charges Coverage, Leverage Analysis, Liquidity Analysis, Per-share Data and Profitability Analysis) and proprietary Wright Quality Rating analyses tables. The Wright Quality Rating, a measure of corporate risk, examines the liquidity of the stock, financial strength, profitability and corporate growth characteristics of Oragenics, Inc.. There is a textual review of the financial results of Oragenics, Inc. versus Cell Therapeutics, Inc., Cyclacel Pharmaceuticals, Inc. and SyntheMed, Inc.. The comparative analysis of these companies compares Sales (sales, sales growth and sales per employee), Company Valuations (Price/Earnings, Price/Book, Price/Sales and 52-Week Price Change) and Financial Position (Long-term Debt/Equity). Also included for Oragenics, Inc. are the Company Description, Recent Stock Performance, Profitability Analysis, Dividend Analysis, and Key Data Items (Ticker, Major Industry, Sub-Industry, Fiscal Year End Month, Employees, Share Type, Market Capitalization, Total Shares Outstanding and Number of Closely Held Shares.) Additional research for Oragenics, Inc. includes tables with up to 10-years of history of computed ratios, sales, earnings, and security prices.